Shots:

• The US FDA has approved the company’s INOmax EVOLVE DS delivery system to be used to deliver INOmax gas, an FDA-approved treatment indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation neonates with hypoxic respiratory failure associated with pulmonary hypertension
• The INOmax EVOLVE DS delivery system delivers INOmax gas into the inspiratory limb of the patient’s breathing circuit to provide a constant concentration of nitric oxide throughout the inspired breath
• The system uses an injector module, designed for tracking gas delivery system waveforms, to deliver synchronized and proportional doses of nitric oxide. INOmax EVOLVE DS is also compatible with ventilators and respiratory care devices

Ref: Mallinckrodt | Image: Mallinckrodt

Related News:- Mallinckrodt’s Terlivaz (terlipressin) Receives the US FDA’s Approval for the Treatment of Hepatorenal Syndrome

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com